Assessing the Efficacy of Monthly 308 nm Excimer Lamp Double-Stacked Pulse Adjusted Therapy for Alopecia Areata.
Alopecia areata
Excimer lamp
Hair loss
SALT
Journal
Skin appendage disorders
ISSN: 2296-9195
Titre abrégé: Skin Appendage Disord
Pays: Switzerland
ID NLM: 101670617
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
received:
22
03
2023
accepted:
01
09
2023
pmc-release:
01
02
2025
medline:
5
2
2024
pubmed:
5
2
2024
entrez:
5
2
2024
Statut:
ppublish
Résumé
Alopecia areata (AA) is an autoimmune disease characterized by T cell-mediated attack on the hair follicle. Although there are a wide range of therapies, the majority of them are not satisfactory due to side effects, pain due to intralesional injections or limited efficacy. In this study, we sought to evaluate the efficacy, influence factors, and safety of 308 nm excimer lamp used in a monthly basis in a double-stacked pulse manner for the treatment of AA. This was a prospective study, using 308 nm excimer lamp in a double-stacked pulse therapy for AA. The primary endpoint was the improvement in SALT score. A total of 40 patients with AA were enrolled in this study. Forty (100%) patients achieved clinical response. Hyperpigmentation and erythema occurred on the treated alopecic areas of all patients but they were considered tolerable. Patients of younger age or with a smaller area of affection had a better overall treatment response. 308 nm excimer lamp therapy is an excellent option for single or multiple AA because it achieves a good clinical response with less adverse effects than other therapies. This therapy may be useful for low-income countries where new JAK inhibitors are not available, however, for patients with extensive hair loss, it is not as effective and thus, it may be unfit for patients with alopecia totalis and alopecia universals.
Identifiants
pubmed: 38313573
doi: 10.1159/000533993
pii: 533993
pmc: PMC10836865
doi:
Types de publication
Journal Article
Langues
eng
Pagination
18-25Informations de copyright
© 2023 S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.